Focus: AstraZeneca is a global Big Pharma with ~90,000 employees headquartered in Cambridge, UK, operating across small molecules, vaccines, and biologics with leading franchises in oncology, cardiovascular, and respiratory disease. The company commands significant scale and market presence as a publicly traded pharmaceutical leader.
Profile data last refreshed 13h ago · AI intelligence enriched 2w ago
Hot — 1954 jobs added in 30d
Net +836 (1954 new, 1118 removed). Aggressive expansion phase.
AstraZeneca is a stable, well-resourced Big Pharma with strong hiring momentum, but career progression depends on pipeline execution in oncology and immunology amid moderate revenue concentration risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Dominant revenue driver representing 37% of company sales; patent protection extends to 2041, ensuring long-term cash generation.
Help build intelligence for AstraZeneca
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from AstraZeneca's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-largest contributor but facing loss of exclusivity; generic competition will likely erode revenue significantly.
Established tyrosine kinase inhibitor in peak commercial phase with patent protection through 2036; oncology franchise anchor.
Kinase inhibitor for non-small cell lung cancer with robust patent life; strong lifecycle position and Phase 4 trial activity (54 trials) indicate ongoing expansion potential.
Respiratory triple-therapy with strong patent protection to 2038; key component of respiratory franchise growth strategy.
Cardiovascular P2Y12 receptor antagonist with solid revenue and patent protection through 2036; represents core CV franchise strength.
PARP inhibitor in peak phase with 52 approved/ongoing indication trials; represents growing precision oncology portfolio.
Faces near-term patent cliff in 2031; represents the company's primary identified LOE risk and restructuring headwind.
Biologic with indefinite patent protection; rare disease franchise anchor with strong orphan market positioning.
Complement inhibitor facing LOE; biologic patent erosion will be gradual but inevitable, requiring pipeline replacements.
108 discontinued, 25 duplicate formulations not shown
+15 more products with revenue data
+2 more
Why is AstraZeneca (LSE:AZN) holding the spotlight as UK pharma stays firm today? - Kalkine Media
Why is AstraZeneca (LSE:AZN) holding the spotlight as UK pharma stays firm today? Kalkine Media
New FDA Nod Keeps Gilead Drug Competitive With AstraZeneca & Daiichi in Breast Cancer - MedCity News
New FDA Nod Keeps Gilead Drug Competitive With AstraZeneca & Daiichi in Breast Cancer MedCity News
AstraZeneca announces major financial investment to bring medical breakthroughs to patients' bedsides - WMAR 2 News Baltimore
AstraZeneca announces major financial investment to bring medical breakthroughs to patients' bedsides WMAR 2 News Baltimore
AstraZeneca Eyes India Launch for Oral GLP-1 Drug - NAVLIN DAILY
AstraZeneca Eyes India Launch for Oral GLP-1 Drug NAVLIN DAILY
AstraZeneca talks offer new hope of breast cancer drug on NHS - The Times
AstraZeneca talks offer new hope of breast cancer drug on NHS The Times
Global drugmakers invest billions to boost US presence - Reuters
Global drugmakers invest billions to boost US presence Reuters
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
+13 more products
+2 more
+2 more
+2 more
+2 more
+2 more
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo